Abstracts for rHEALTH’s Factor VIII and Platelet Tests Accepted for Poster and Oral Presentations at Upcoming AACC 2019 Meeting
CAMBRIDGE, Mass., July 11, 2019 – rHEALTH LLC and its affiliate DNA Medicine Institute, Inc. today announced that two of its abstracts have been accepted via peer review for presentation at the 2019 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting. The abstracts are:
Point-of-Care FVIII Test Using an Integrated Microfluidic Consumable with a Fluorogenic Assay (Poster A-293) – August 6, 2019, 9:30 AM, Session 07: Hematology and Coagulation
Point-of-Care Microvolume Cytometer Measures Platelet Counts with High Accuracy from Capillary Blood (Invited Oral Presentation) – August 6, 2019, 2:15–2:30 PM
“We are excited to share these results with the laboratory medicine community,” said Dr. Eugene Chan, President and CEO. “These abstracts demonstrate that two complex and clinically critical tests can be implemented at the point-of-care with high accuracy using the rHEALTH technology.”
The point-of-care FVIII test enables hemophilia A patients and providers to prevent breakthrough bleeding and allows early detection of inhibitors. Likewise, the microvolume platelet test supports proper management of thrombocytopenia, a condition that can result from certain medications or immune disorders.
The rHEALTH blood sensor technology is an award-winning, patented platform that has received funding from NASA, NIH, and XPRIZE. It is currently being used in collaborations with academic institutions and biopharmaceutical companies. Designed for fingerstick blood samples, the technology generates results in under 30 minutes, enabling use by both consumers and medical professionals.
The 2019 AACC Annual Scientific Meeting & Clinical Lab Expo is the 71st annual conference for laboratory medicine professionals, attracting over 20,000 attendees. The event, held in Anaheim, California, from August 4–8, will showcase cutting-edge science and technology in clinical diagnostics.
About rHEALTH®
rHEALTH develops and commercializes its Diagnose Yourself, Anywhere™ technology, including:
rHEALTH Diagnostic Platform – enabling multiple laboratory tests from a single small-volume blood sample at the point-of-care.
SKYE Sensor – a wireless wearable providing comprehensive real-time vital signs monitoring.
CHAS – a user-friendly mobile application supporting health management.
For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator dedicated to advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, NIH, and the Bill & Melinda Gates Foundation, leveraging interdisciplinary science and engineering expertise to solve complex biomedical problems.
For more information, visit www.dnamedinstitute.com.
Media Contact:
Rebecca Yu
(617) 913-7630
pr@rhealth.com